By Rising Star Stocks 
Northrop Grumman just delivered its best quarter in recent memory. The stock is still down about 32% from its March 2026 peak of $774. That is the whole debate in one sentence.
On July 21, before the market opened, NOC reported Q2 2026 sales of $10.9 billion, up 5% year-over-year, and beat EPS consensus by a notable margin: $7.68 actual versus $6.82 expected, a 12.6% surprise. Management simultaneously raised full-year MTM-adjusted EPS guidance to $28.60–$29.10, up from $27.40–$27.90, and lifted sales guidance to $43.75B–$44.25B. The company also disclosed a record backlog of about $105 billion (reported as $104.7 billion), supported by $20 billion of net awards in the quarter.
The stock responded. Shares moved higher after the report. But the chart still shows a name that traded as high as $774 in early March and was sitting around $525 the week before earnings. That is not a minor dip.
What Drove the Selloff From the Peak
Two things pulled NOC from its highs. First, the B-21 Raider program carries a $1.0 billion remaining loss accrual (as of March 31, 2026). That is a headwind on reported margins that investors spent the spring repricing. Second, the broader defense sector saw institutional rotation as rate expectations shifted and some of the geopolitical premium baked in early 2026 faded.
Neither of those issues disappeared in Q2. The B-21’s Low Rate Initial Production phase is still absorbing losses, and the Sentinel ICBM modernization program carries its own execution risk. Aeronautics did lead year-to-date growth, up 15%, in part because prior-year B-21 loss charges did not recur in the same way. But the cumulative loss accrual is still sitting there.
Here’s where it gets interesting. The 52-week analyst price target average is approximately $670. The stock trades near $525. That is a 27% gap between where the Street thinks it belongs and where it is actually trading. The 52-week high is $774. The current price is roughly 32% below that.
The Defense Budget Tailwind Is Real
The macro backdrop for Northrop is arguably as favorable as it has been in a decade. A proposed $1.5 trillion U.S. defense spending framework, ongoing NATO allied procurement, and demand for advanced aircraft, missile defense, and space systems are all pulling in the same direction. Net Q2 awards came in at $20 billion, the same quarter the backlog crossed about $105 billion for the first time.
That backlog number is worth pausing on. About a $105 billion contracted book against roughly $44 billion in annual revenue is nearly 2.4 years of forward sales visibility. That is not a company guessing at its revenue line. Most of the revenue for the next two-plus years is already under contract.
Slight tangent: the space and deterrence businesses are the parts of Northrop that get underweighted in most valuation discussions. Aeronautics gets all the B-21 attention. But the Mission Systems segment — sensors, radar, C4ISR — is guiding to high $12 billion in sales with roughly 15% operating margins. That is a quietly high-margin business inside a defense company being valued primarily on a troubled bomber program.
Options Market Analysis
With earnings now behind it, the IV on NOC options has settled back toward normal levels. The market’s immediate reaction to the Q2 beat was constructive, but NOC is not a high-vol name. The implied move heading into July 21 was priced around 9.2%, and the actual move came in smaller.
The next hard catalyst is Q3 earnings, expected in October. Between now and then, the trade is about whether the guidance raise and record backlog close the valuation gap to the Street’s targets.
Bull case: For traders expecting the guidance raise and record backlog to pull institutional money back into NOC, a defined-risk call spread targeting $560–$590 into late Q3 captures the re-rating while limiting downside. Free cash flow guidance of $3.1B–$3.5B for 2026 provides a floor on the valuation argument.
Bear case: For traders expecting the B-21 loss accrual to widen or program delays to surface, a put spread anchored below the recent $496 trading-range low defines the risk. The unresolved $1.0 billion remaining loss accrual is the trigger to watch.
Neutral case: For traders expecting NOC to consolidate in the $510–$550 range while the fundamental case builds, a covered call or short put at a discount to current levels collects premium while the backlog-to-valuation gap closes over multiple quarters.
Risk Analysis
The operating margin picture is complicated. Q2 operating margin came in at 10.1%, versus 13.8% a year earlier. Most of that decline is explained by the prior-year divestiture gain and lower pension/CAS adjustment — not a deterioration in the underlying business. But margin trajectory matters for how the Street re-rates the stock, and any further Raider-related charges would extend the compression.
The broader execution risk is real: programs of the complexity and scale of the B-21 and Sentinel have historically produced cost surprises. The current $1.0 billion loss accrual is management’s best estimate of what remains. If the program runs hotter than that, the next earnings call gets harder.
Forward Outlook
Reaffirmed free cash flow guidance of $3.1B–$3.5B for 2026, a record ~$105B backlog, and a raised EPS midpoint near $28.85 are the three numbers that matter. At roughly $525, NOC trades at approximately 18x the midpoint of its raised 2026 EPS guidance. The 52-week analyst average target near $670 implies the stock should trade closer to 23x. The gap between those two multiples is the entire NOC investment debate right now.
The Q2 beat is done. The backlog is on the record. The question that remains open is whether the B-21 program overhang and the margin compression from pension and divestiture comparisons are already fully reflected in a 32% discount to the year’s high — or if there is more repricing left before the recovery starts. That answer will not come until October.